Mark A Kane

Summary

Publications

  1. ncbi Chapter 15: HPV vaccine use in the developing world
    Mark A Kane
    World Health Organization, Seattle, WA, USA
    Vaccine 24:S3/132-9. 2006
  2. doi Human papillomaviruses (HPV) vaccines: implementation and communication issues
    Mark A Kane
    4816 West Mercer Way, Mercer Island, WA 98040, USA
    J Fam Plann Reprod Health Care 34:3-4. 2008
  3. ncbi The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization
    M A Kane
    Consultant on Immunization Policy, Mercer Island, WA, United States Electronic address
    Vaccine 31:J15-20. 2013
  4. doi Implementation of human papillomavirus immunization in the developing world
    Mark A Kane
    Consultant on Immunization Policy, Mercer Island, WA, USA Electronic address
    Vaccine 30:F192-200. 2012
  5. doi Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine
    Mark A Kane
    Consultant, Mercer Island, WA 98040, USA
    Gynecol Oncol 117:S32-5. 2010
  6. doi Preventing cancer with vaccines: progress in the global control of cancer
    Mark A Kane
    Mercer Island, Washington, USA
    Cancer Prev Res (Phila) 5:24-9. 2012
  7. ncbi New immunization initiatives and progress toward the global control of hepatitis B
    Mark A Kane
    Children s Vaccine Program at PATH Program for Appropriate Technology in Health, Seattle, Washington 98107, USA
    Curr Opin Infect Dis 15:465-9. 2002
  8. ncbi Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan
    Mark A Kane
    Cancer Epidemiol Biomarkers Prev 12:2-3. 2003

Detail Information

Publications8

  1. ncbi Chapter 15: HPV vaccine use in the developing world
    Mark A Kane
    World Health Organization, Seattle, WA, USA
    Vaccine 24:S3/132-9. 2006
    ....
  2. doi Human papillomaviruses (HPV) vaccines: implementation and communication issues
    Mark A Kane
    4816 West Mercer Way, Mercer Island, WA 98040, USA
    J Fam Plann Reprod Health Care 34:3-4. 2008
  3. ncbi The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization
    M A Kane
    Consultant on Immunization Policy, Mercer Island, WA, United States Electronic address
    Vaccine 31:J15-20. 2013
    ..Approximately 10% of the adult population of China remain chronic carriers of hepatitis B virus and cannot be helped by the vaccine, so prevention of liver cancer and cirrhosis in those groups remains a future challenge for China...
  4. doi Implementation of human papillomavirus immunization in the developing world
    Mark A Kane
    Consultant on Immunization Policy, Mercer Island, WA, USA Electronic address
    Vaccine 30:F192-200. 2012
    ..This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012...
  5. doi Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine
    Mark A Kane
    Consultant, Mercer Island, WA 98040, USA
    Gynecol Oncol 117:S32-5. 2010
    ..Countries will need to decide on the priority of HPV control in the context of other important new vaccines against pneumococcal pneumonia and rotavirus diarrhea...
  6. doi Preventing cancer with vaccines: progress in the global control of cancer
    Mark A Kane
    Mercer Island, Washington, USA
    Cancer Prev Res (Phila) 5:24-9. 2012
    ....
  7. ncbi New immunization initiatives and progress toward the global control of hepatitis B
    Mark A Kane
    Children s Vaccine Program at PATH Program for Appropriate Technology in Health, Seattle, Washington 98107, USA
    Curr Opin Infect Dis 15:465-9. 2002
    ..This review discusses the implication of these changes for global control of hepatitis B with vaccine, which is now progressing rapidly...
  8. ncbi Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan
    Mark A Kane
    Cancer Epidemiol Biomarkers Prev 12:2-3. 2003